e-MedSoft.com opens wireless portale-MedSoft.com, a provider of Internet-based software products designed to improve workflow efficiencies in the healthcare environment, has integrated wireless technology into its entire product line. This newly
e-MedSoft.com opens wireless portal
e-MedSoft.com, a provider of Internet-based software products designed to improve workflow efficiencies in the healthcare environment, has integrated wireless technology into its entire product line. This newly developed wireless technology is embedded in e-MedSoft.coms core server technology, which allows the wireless user to access all of e-MedSofts products from any handheld or wireless device. Jacksonville, FL-based e-MedSoft has also developed privacy templates based on its own proprietary security technology and has acquired a 30-year license on more than 11 patents for CypherLXS security technology, developed by CypherSoft. e-MedSoft will issue approximately 1.5 million shares of common stock to CypherSoft as well as joint development advances of $750,000 for a 15% equity stake in Cyphersoft and its affiliates and a seat on the board.
In related developments, e-MedSoft executed a $23 million merger agreement with Camarillo, CA-based VirTx, a provider of collaborative medical networks that use Web-enabled, multimedia clinical applications such as live-interactive videoconferencing hosted via ASP technology. VirTx will become e-MedSofts new Multi-Media Division.
© 2000 Miller Freeman, Inc., a United News & Media company.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.